Our News Bureau – Mumbai
Daiichi Sankyo Company and Ranbaxy Laboratories announced that ‘Terapia Ranbaxy’, a subsidiary of Ranbaxy in Romania, will launch Sevikar, a fixed dose combination (FDC) of olmesartan medoxomil and amlodipine besylate tablets, in Romania. Sevikar will be available in three strengths of 5/20 mg (amlodipine besylate 5 mg, olmesartan medoxomil 20 mg), 5/40 mg (amlodipine besylate 5mg, olmesartan medoxomil 40 mg) and 10/40 mg (amlodipine besylate 10mg, olmesartan medoxomil 40 mg). The product is expected to be included on the national lists of compensated drugs benefiting patients as it will be made available at an affordable price.
Arun Sawhney, Chief Executive Officer and Managing Director, Ranbaxy said, “Terapia Ranbaxy is committed to offer safe and affordable medicines to its customers and patients in Romania. We are pleased to introduce the first combination of olmesartan + amlodipine for the treatment of hypertension, which is a major public health problem. Leveraging synergies with Daiichi Sankyo is part of our business strategy and this will be our third product introduction as part of the Hybrid Business Model.”
“We are pleased to announce the synergistic business development with Ranbaxy in Romania. We are determined to work with Ranbaxy to further serve diversifying medical needs in this strongly emerging region,” said Joji Nakayama, President and Chief Executive Officer, Daiichi Sankyo.
Sevikar is a once-daily, single pill FDC of the angiotensin receptor blocker olmesartan medoxomil, an antihypertensive originally discovered by Daiichi Sankyo, and the calcium channel blocker amlodipine besylate. The new product is indicated for the treatment of hypertensive patients inadequately controlled on monotherapy regimes (olmesartan or amlodipine alone). This unique combination provides safe blood pressure decline effect through the complementary actions of its two ingredients. This combination therapy is well tolerated and is associated with a lower incidence of side effects, such as oedema, compared to monotherapy with high amlodipine dosages (10 mg).